Modality
Bispecific Ab
MOA
CDK2i
Target
EGFR
Pathway
Neuroinflam
NSCLC
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
Aug 2022
→ Dec 2027
Phase 2Current
NCT07591896
680 pts·NSCLC
2022-10→TBD·Terminated
NCT05867599
556 pts·NSCLC
2022-08→2027-12·Not yet recruiting
1,236 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-241.7y awayPh3 Readout· NSCLC
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2027-12-24 · 1.7y away
NSCLC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07591896 | Phase 2/3 | NSCLC | Terminated | 680 | CR |
| NCT05867599 | Phase 2/3 | NSCLC | Not yet recr... | 556 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |